Dealing With Epilepsy In The Right Way

Epilepsy affects more than 60 million people around the world. Despite obtaining two or more approved drug therapies, more than 40% of patients develop medication resistance throughout their illness. The Bright Minds Biosciences team is dedicated to developing the next generation of serotonin drugs that can specifically target particular conditions, resulting in a significant reduction in side effects and increased clinical action, ultimately changing the lives of patients.

Leave a Reply

Your email address will not be published. Required fields are marked *